Executive Transition - PharmaCorp RX Inc. announced the appointment of Paul Dale as President and Chief Operating Officer effective December 1, 2025, as Calvin LeRoux transitions to a one-year role as Strategic Advisor to the CEO [1][2] - Paul Dale has been with PharmaCorp since its inception as Chief Operating Officer and will now take on broader leadership responsibilities to support the company's national expansion strategy [2] - Calvin LeRoux will assist in the transition and continue to provide guidance on strategic initiatives and matters related to PharmaChoice Canada in his new advisory role [2] New Appointment - Sophia Sigler will join PharmaCorp as Director of Business Development effective December 1, 2025, leading business development initiatives, including sourcing acquisition opportunities and managing the transaction pipeline [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [3] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [3]

Core Points - PharmaCorp Rx Inc. has received approval from the TSX Venture Exchange for the supplemental listing of 27,427,500 common share purchase warrants, expected to trade under the symbol PCRX.WT starting November 17, 2025 [1][2] - The Offering closed on November 12, 2025, with a total of 54,855,000 Units issued, each consisting of one common share and one-half of a common share purchase warrant, with an exercise price of $0.50 per Warrant Share [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [4] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [4]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 47.7 million units at C$0.42 per unit, aiming to raise C$20.0 million due to strong investor demand [1][3] Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2] - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3] - An over-allotment option allows underwriters to purchase an additional 15% of the units sold to cover over-allotments [4] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Group 3: Company Overview - PharmaCorp is focused on acquiring and operating community pharmacies in Canada, empowering pharmacists as equity partners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies [8]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 35.7 million units at a price of C$0.42 per unit, aiming to raise gross proceeds of C$15.0 million for future acquisitions and working capital [1][3]. Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2]. - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3]. - The underwriters have an over-allotment option to purchase an additional 15% of the units sold to cover over-allotments and for market stabilization [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards future acquisition opportunities and general working capital requirements [3]. Group 3: Company Overview - PharmaCorp is a Canadian pharmacy acquisition platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [7]. - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies across Canada [8].

Core Viewpoint - PharmaCorp Rx Inc. reported strong operational momentum and financial results for Q2 2025, highlighting its national acquisition strategy and growth in pharmacy-level contributions [2][4]. Financial Highlights - The company generated revenues from three operating pharmacies, with same-store sales increasing by 11.3% year-over-year compared to Q2 2024 [8]. - Prescription volumes rose by 3.5% year-over-year, indicating sustained patient engagement [8]. - The net loss for the quarter was attributed to investments in corporate infrastructure and deferred executive compensation from 2024 [5][8]. Operational Update - Key investments were made in systems, personnel, and integration processes to support scalable national growth [5]. - The company completed the acquisition of its fourth pharmacy in Western Canada, enhancing its national footprint [6][8]. Subsequent Events - On August 13, 2025, PharmaCorp entered into a credit agreement with CIBC, providing up to $20.5 million in committed credit facilities to support its acquisition strategy [7]. - A separate $5 million credit facility was established to support the Pharmacist Co-Ownership Program, enabling pharmacists to acquire ownership positions [7]. Pipeline Progress - PharmaCorp is actively working to finalize purchase and sale agreements related to previously announced letters of intent, expecting to close additional transactions in the second half of the year [9]. Company Overview - PharmaCorp Rx Inc. focuses on empowering pharmacists to become equity partners while supporting the continuity of care and succession for retiring pharmacy owners [12]. - The company operates four PharmaChoice Canada bannered pharmacies and aims to acquire more pharmacies under this brand [12].